196 related articles for article (PubMed ID: 26070873)
1. Olfactomedin-related proteins 4 (OLFM4) expression is involved in early gastric carcinogenesis and of prognostic significance in advanced gastric cancer.
Jang BG; Lee BL; Kim WH
Virchows Arch; 2015 Sep; 467(3):285-94. PubMed ID: 26070873
[TBL] [Abstract][Full Text] [Related]
2. OLFM4 is associated with lymph node metastasis and poor prognosis in patients with gastric cancer.
Luo Z; Zhang Q; Zhao Z; Li B; Chen J; Wang Y
J Cancer Res Clin Oncol; 2011 Nov; 137(11):1713-20. PubMed ID: 21904905
[TBL] [Abstract][Full Text] [Related]
3. Serum olfactomedin 4 (GW112, hGC-1) in combination with Reg IV is a highly sensitive biomarker for gastric cancer patients.
Oue N; Sentani K; Noguchi T; Ohara S; Sakamoto N; Hayashi T; Anami K; Motoshita J; Ito M; Tanaka S; Yoshida K; Yasui W
Int J Cancer; 2009 Nov; 125(10):2383-92. PubMed ID: 19670418
[TBL] [Abstract][Full Text] [Related]
4. Expression and significance of homeodomain protein Cdx2 in gastric carcinoma and precancerous lesions.
Qin R; Wang NN; Chu J; Wang X
World J Gastroenterol; 2012 Jul; 18(25):3296-302. PubMed ID: 22783055
[TBL] [Abstract][Full Text] [Related]
5. A quantitative proteomics study on olfactomedin 4 in the development of gastric cancer.
Ran X; Xu X; Yang Y; She S; Yang M; Li S; Peng H; Ding X; Hu H; Hu P; Zhang D; Ren H; Wu L; Zeng W
Int J Oncol; 2015 Nov; 47(5):1932-44. PubMed ID: 26398045
[TBL] [Abstract][Full Text] [Related]
6. The Intestinal Stem Cell Marker SMOC2 Is an Independent Prognostic Marker Associated With Better Survival in Gastric Cancer.
Hyun CL; Park SJ; Kim HS; Song HJ; Kim HU; Lee C; Lee DH; Maeng YH; Kim YS; Jang B
Anticancer Res; 2021 Jul; 41(7):3689-3698. PubMed ID: 34230168
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemically detectable Cdx2 is present in intestinal phenotypic elements in early gastric cancers of both differentiated and undifferentiated types, with no correlation to non-neoplastic surrounding mucosa.
Mizoshita T; Tsukamoto T; Inada K; Ogasawara N; Hirata A; Kato S; Joh T; Itoh M; Yamamura Y; Tatematsu M
Pathol Int; 2004 Jun; 54(6):392-400. PubMed ID: 15144397
[TBL] [Abstract][Full Text] [Related]
8. Olfactomedin-4 in digestive diseases: A mini-review.
Wang XY; Chen SH; Zhang YN; Xu CF
World J Gastroenterol; 2018 May; 24(17):1881-1887. PubMed ID: 29740203
[TBL] [Abstract][Full Text] [Related]
9. Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer.
Zhang X; Tsukamoto T; Mizoshita T; Ban H; Suzuki H; Toyoda T; Tatematsu M
Oncol Rep; 2009 Mar; 21(3):609-13. PubMed ID: 19212618
[TBL] [Abstract][Full Text] [Related]
10. Expression of pyruvate dehydrogenase is an independent prognostic marker in gastric cancer.
Sun XR; Sun Z; Zhu Z; Guan HX; Li CY; Zhang JY; Zhang YN; Zhou H; Zhang HJ; Xu HM; Sun MJ
World J Gastroenterol; 2015 May; 21(17):5336-44. PubMed ID: 25954108
[TBL] [Abstract][Full Text] [Related]
11. Low expression of olfactomedin 4 correlates with poor prognosis in smoking patients with non-small cell lung cancer.
Su W; Luo L; Wu F; Lai Z; Li X; Xie Z; Tang Z; Yang Z; Liang R
Hum Pathol; 2015 May; 46(5):732-8. PubMed ID: 25771901
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma.
Jun SY; An S; Huh T; Chung JY; Hong SM
Pathol Res Pract; 2020 May; 216(5):152940. PubMed ID: 32276789
[TBL] [Abstract][Full Text] [Related]
13. Gene expression profiling of metaplastic lineages identifies CDH17 as a prognostic marker in early stage gastric cancer.
Lee HJ; Nam KT; Park HS; Kim MA; Lafleur BJ; Aburatani H; Yang HK; Kim WH; Goldenring JR
Gastroenterology; 2010 Jul; 139(1):213-25.e3. PubMed ID: 20398667
[TBL] [Abstract][Full Text] [Related]
14. The combined expression of metaplasia biomarkers predicts the prognosis of gastric cancer.
Suh YS; Lee HJ; Jung EJ; Kim MA; Nam KT; Goldenring JR; Yang HK; Kim WH
Ann Surg Oncol; 2012 Apr; 19(4):1240-9. PubMed ID: 22048633
[TBL] [Abstract][Full Text] [Related]
15. Feasibility of olfactomedin 4 as a molecular biomarker for early diagnosis of gastric neoplasia after intestinal metaplasia.
Pang L; Yan X; Su D; Wu X; Jiang H
Scand J Gastroenterol; 2023 Feb; 58(2):133-141. PubMed ID: 36124708
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of the Receptor for Advanced Glycation Endproducts (RAGE) is associated with poor prognosis in gastric cancer.
Wang D; Li T; Ye G; Shen Z; Hu Y; Mou T; Yu J; Li S; Liu H; Li G
PLoS One; 2015; 10(4):e0122697. PubMed ID: 25860956
[TBL] [Abstract][Full Text] [Related]
17. MAGE-A family is involved in gastric cancer progression and indicates poor prognosis of gastric cancer patients.
Lian Y; Sang M; Gu L; Liu F; Yin D; Liu S; Huang W; Wu Y; Shan B
Pathol Res Pract; 2017 Aug; 213(8):943-948. PubMed ID: 28647208
[TBL] [Abstract][Full Text] [Related]
18. Protein expression of HER2, 3, 4 in gastric cancer: correlation with clinical features and survival.
He XX; Ding L; Lin Y; Shu M; Wen JM; Xue L
J Clin Pathol; 2015 May; 68(5):374-80. PubMed ID: 25731189
[TBL] [Abstract][Full Text] [Related]
19. S100 calcium-binding protein A4 is a novel independent prognostic factor for the poor prognosis of gastric carcinomas.
Zhao Y; Zhang T; Wang Q
Oncol Rep; 2013 Jul; 30(1):111-8. PubMed ID: 23612849
[TBL] [Abstract][Full Text] [Related]
20. CCR6 overexpression predicted advanced biological behaviors and poor prognosis in patients with gastric cancer.
Zhang XG; Song BT; Liu FJ; Sun D; Wang KX; Qu H
Clin Transl Oncol; 2016 Jul; 18(7):700-7. PubMed ID: 26489425
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
